CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Five-year overall survival (OS) and OS by baseline liver function from the Phase 3 HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
DOI 10.1055/s-0045-1810979
Bibliografische Angaben
Nachweis in CareLit
Autor:innenT Wirth, M Kudo, L Rimassa, S L Chan, B Sangro, G Lau, V Breder, M Varela, O V Crysler, M Bouattour, T V Dao, A Faccio, J Furuse, L-B Jeng, Y-K Kang, R K Kelley, M J Paskow, M Makowsky, D Ran, A Negro, G K Abou-Alfa
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe08/2025
Jahrgang / SeitenJg. 63 · S. e552-e553
Kernaussage aus der Literatur
Abstract-Vorschau
Five-year overall survival (OS) and OS by baseline liver function from the Phase 3 HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
Zitieren
Zitierempfehlung
T Wirth, M Kudo, L Rimassa, S L Chan, B Sangro, G Lau, V Breder, M Varela, O V Crysler, M Bouattour, T V Dao, A Faccio, J Furuse, L-B Jeng, Y-K Kang, R K Kelley, M J Paskow, M Makowsky, D Ran, A Negro, G K Abou-Alfa (2025) Five-year overall survival (OS) and OS by baseline liver function from the Phase 3 HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC). Zeitschrift für Gastroenterologie, 63 (08), e552-e553. https://doi.org/10.1055/s-0045-1810979
Mit CareLit weiterarbeiten